^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    FF-10502

    i
    Other names: FF-10502, FF-10502-01
    Company:
    Fujifilm Holdings
    Drug class:
    DNA synthesis inhibitor
    Related drugs:
    1year
    A phase 1/2a safety, pharmacokinetics, and efficacy study of the novel nucleoside analog FF-10502-01 for the treatment of advanced solid tumors. (PubMed, Cancer)
    FF-10502-01 was well tolerated with manageable side effects and limited hematologic toxicity. Durable PRs and disease stabilizations were observed in heavily pretreated biliary tract patients who had received prior gemcitabine. FF-10502-01 is distinct from gemcitabine and may represent an effective therapy.
    P1/2 data • PK/PD data • Clinical Trial,Phase I • Journal • Metastases
    |
    PBRM1 (Polybromo 1) • BAP1 (BRCA1 Associated Protein 1)
    |
    PBRM1 mutation • BAP1 mutation
    |
    cisplatin • gemcitabine • FF-10502